Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I Trial

Patricia A. Thompson, Chiu Hsieh Hsu, Sylvan Green, Alison T. Stopeck, Karen Johnson, David S. Alberts, H. H.Sherry Chow

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Regular use of nonsteroidal anti-inflammatory drugs (NSAID) has been associated with reduced risk of breast cancer. Sulindac, a nonselective NSAID with both cyclooxygenase-2-dependent and -independent activities, is a candidate for breast chemoprevention. We conducted a phase Ib trial in 30 women at increased risk for breast cancer to evaluate the breast tissue distribution of sulindac at two dose levels (150 mg daily and 150mgtwice daily for 6weeks), using nipple aspirate fluid (NAF) as a surrogate of breast tissue drug exposure. We also explored the effect of sulindac on drug-induced biomarkers in NAF. We show that sulindac and its metabolites partition to human breast as measured by NAF levels. Sulindac intervention did not decrease 13,14-dihydro-15-keto prostaglandin A2, a stable derivative of prostaglandin E2, in NAF, but exposure was associated with a significant trend towards higher levels of growth differentiation factor 15 in NAF in women receiving 150 mg twice daily (P = 0.038). These results are the first to show partitioning of sulindac and metabolites to human breast tissue and the first evidence for a potential dose-dependent effect of sulindac on growth differentiation factor 15 levels in NAF.

Original languageEnglish (US)
Pages (from-to)101-107
Number of pages7
JournalCancer Prevention Research
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I Trial'. Together they form a unique fingerprint.

  • Cite this